661 related articles for article (PubMed ID: 28373672)
21. Potential clinical utility of ultrasensitive circulating tumor DNA detection with CAPP-Seq.
Bratman SV; Newman AM; Alizadeh AA; Diehn M
Expert Rev Mol Diagn; 2015 Jun; 15(6):715-9. PubMed ID: 25773944
[TBL] [Abstract][Full Text] [Related]
22. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer.
Villaflor V; Won B; Nagy R; Banks K; Lanman RB; Talasaz A; Salgia R
Oncotarget; 2016 Oct; 7(41):66880-66891. PubMed ID: 27602770
[TBL] [Abstract][Full Text] [Related]
23. Next-Generation Sequencing of Tissue and Circulating Tumor DNA: The UC San Diego Moores Center for Personalized Cancer Therapy Experience with Breast Malignancies.
Shatsky R; Parker BA; Bui NQ; Helsten T; Schwab RB; Boles SG; Kurzrock R
Mol Cancer Ther; 2019 May; 18(5):1001-1011. PubMed ID: 30926636
[TBL] [Abstract][Full Text] [Related]
24. Design of a Targeted Sequencing Assay to Detect Rare Mutations in Circulating Tumor DNA.
Chen J; Chen J; He F; Huang Y; Lu S; Fan H; Wang M; Xu R
Genet Test Mol Biomarkers; 2019 Apr; 23(4):264-269. PubMed ID: 30986100
[TBL] [Abstract][Full Text] [Related]
25. Using circulating cell-free DNA to monitor personalized cancer therapy.
Oellerich M; Schütz E; Beck J; Kanzow P; Plowman PN; Weiss GJ; Walson PD
Crit Rev Clin Lab Sci; 2017 May; 54(3):205-218. PubMed ID: 28393575
[TBL] [Abstract][Full Text] [Related]
26. Liquid biopsy-based comprehensive gene mutation profiling for gynecological cancer using CAncer Personalized Profiling by deep Sequencing.
Iwahashi N; Sakai K; Noguchi T; Yahata T; Matsukawa H; Toujima S; Nishio K; Ino K
Sci Rep; 2019 Jul; 9(1):10426. PubMed ID: 31320709
[TBL] [Abstract][Full Text] [Related]
27. [Lung cancer molecular testing, what role for Next Generation Sequencing and circulating tumor DNA].
Pécuchet N; Legras A; Laurent-Puig P; Blons H
Ann Pathol; 2016 Jan; 36(1):80-93. PubMed ID: 26803564
[TBL] [Abstract][Full Text] [Related]
28. Next generation sequencing in cancer: opportunities and challenges for precision cancer medicine.
Paolillo C; Londin E; Fortina P
Scand J Clin Lab Invest Suppl; 2016; 245():S84-91. PubMed ID: 27542004
[TBL] [Abstract][Full Text] [Related]
29. Blood-Based Next-Generation Sequencing Analysis of Appendiceal Cancers.
Shaib WL; Zakka K; Staley C; Roberts A; Akce M; Wu C; Alese OB; El-Rayes BF
Oncologist; 2020 May; 25(5):414-421. PubMed ID: 31784493
[TBL] [Abstract][Full Text] [Related]
30. Targeted Next-Generation Sequencing of Circulating Tumor DNA Mutations among Metastatic Breast Cancer Patients.
Sun MY; Lin FQ; Chen LJ; Li H; Lin WQ; Du HY; Yang XX; Li M
Curr Oncol; 2021 Jun; 28(4):2326-2336. PubMed ID: 34202466
[TBL] [Abstract][Full Text] [Related]
31. High-Throughput and Sensitive Quantification of Circulating Tumor DNA by Microfluidic-Based Multiplex PCR and Next-Generation Sequencing.
Guan Y; Mayba O; Sandmann T; Lu S; Choi Y; Darbonne WC; Leveque V; Ryner L; Humke E; Tam NWR; Sujathasarma S; Cheung A; Bourgon R; Lackner MR; Wang Y
J Mol Diagn; 2017 Nov; 19(6):921-932. PubMed ID: 28867605
[TBL] [Abstract][Full Text] [Related]
32. The feasibility of using mutation detection in ctDNA to assess tumor dynamics.
Yi X; Ma J; Guan Y; Chen R; Yang L; Xia X
Int J Cancer; 2017 Jun; 140(12):2642-2647. PubMed ID: 28124376
[TBL] [Abstract][Full Text] [Related]
33. Leveraging the Fragment Length of Circulating Tumour DNA to Improve Molecular Profiling of Solid Tumour Malignancies with Next-Generation Sequencing: A Pathway to Advanced Non-invasive Diagnostics in Precision Oncology?
Underhill HR
Mol Diagn Ther; 2021 Jul; 25(4):389-408. PubMed ID: 34018157
[TBL] [Abstract][Full Text] [Related]
34. Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay.
Schwaederle M; Husain H; Fanta PT; Piccioni DE; Kesari S; Schwab RB; Banks KC; Lanman RB; Talasaz A; Parker BA; Kurzrock R
Oncotarget; 2016 Mar; 7(9):9707-17. PubMed ID: 26848768
[TBL] [Abstract][Full Text] [Related]
35. Mutational landscape of gastric cancer and clinical application of genomic profiling based on target next-generation sequencing.
Cai H; Jing C; Chang X; Ding D; Han T; Yang J; Lu Z; Hu X; Liu Z; Wang J; Shang L; Wu S; Meng P; Lin L; Zhao J; Nie M; Yin K
J Transl Med; 2019 Jun; 17(1):189. PubMed ID: 31164161
[TBL] [Abstract][Full Text] [Related]
36. Complexity of genome sequencing and reporting: Next generation sequencing (NGS) technologies and implementation of precision medicine in real life.
Morganti S; Tarantino P; Ferraro E; D'Amico P; Viale G; Trapani D; Duso BA; Curigliano G
Crit Rev Oncol Hematol; 2019 Jan; 133():171-182. PubMed ID: 30661654
[TBL] [Abstract][Full Text] [Related]
37. Detection of circulating tumor DNA in patients with advanced non-small cell lung cancer.
Yao Y; Liu J; Li L; Yuan Y; Nan K; Wu X; Zhang Z; Wu Y; Li X; Zhu J; Meng X; Wei L; Chen J; Jiang Z
Oncotarget; 2017 Jan; 8(2):2130-2140. PubMed ID: 27791985
[TBL] [Abstract][Full Text] [Related]
38. Performance of a novel Next Generation Sequencing circulating tumor DNA (ctDNA) platform for the evaluation of samples from patients with metastatic breast cancer (MBC).
Gerratana L; Zhang Q; Shah AN; Davis AA; Zhang Y; Wehbe F; Qiang W; Flaum L; Finkelman BS; Gradishar WJ; Platanias LC; Behdad A; Cristofanilli M
Crit Rev Oncol Hematol; 2020 Jan; 145():102856. PubMed ID: 31884205
[TBL] [Abstract][Full Text] [Related]
39. Next-generation sequencing of circulating tumor DNA for metastatic non-small cell lung cancer: a discussion on its implementation in the Brazilian clinical practice.
H Araujo L; Ferreira CG; Baldotto CS; Mathias C; Castro G; Coudry R
Future Oncol; 2021 Jan; 17(2):205-213. PubMed ID: 33052747
[TBL] [Abstract][Full Text] [Related]
40. Bioinformatics Analysis for Cell-Free Tumor DNA Sequencing Data.
Chen S; Liu M; Zhou Y
Methods Mol Biol; 2018; 1754():67-95. PubMed ID: 29536438
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]